Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 347

Sort by

Sort Order Select

Journal Articles

Comprehensive Analysis of Genotype and Prior Exposures in Therapy-Related Myeloid Neoplasms (t-MNs)

Veronica A Guerra, MD, Yan Yuanqing, PhD, Joanne Hsu, BS, Feng Wang, PhD, Mansour Alfayez, MD, Kiyomi Morita, MD, Xingzhi Song, PhD, Courtney D. DiNardo, MD MSc, Marina Y Konopleva, MD PhD, Gautam M. Borthakur, MD, Guillermo Montalban Bravo, MD, Jianhua Zhang, PhD, Latasha Little, BS, Curtis Gumbs, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD, Andrew Futreal, PhD, Koichi Takahashi, MD

Blood (2019) 134 (Supplement_1): 458.

https://doi.org/10.1182/blood-2019-127498

Published: 2019

Journal Articles

NCAPD3 Regulates Tumor Growth and Predicts Prognosis in Diffuse Large B-Cell Lymphoma

Juan Yang, MM, Ying Li, MD, Ya Zhang, MD, Xiangxiang Zhou, MD, Yi Zhao, MM, Yang Han, MM, Jiarui Liu, MM, Xin Wang, MD PhD

Blood (2019) 134 (Supplement_1): 5045.

https://doi.org/10.1182/blood-2019-123910

Published: 2019

Journal Articles

Development of an Immunotherapeutic Monoclonal Antibody Recognizing DKK1-HLA-A2 Complex to Treat Human Hematologic Malignancies

Jianfei Qian, PhD, Qiang Wang, PhD, Lintao Liu, PhD, Enguang Bi, PhD, Xingzhe Ma, PhD, Pan Su, PhD, Maojie Yang, Qing Yi, MD PhD

Blood (2019) 134 (Supplement_1): 5551.

https://doi.org/10.1182/blood-2019-123541

Published: 2019

Journal Articles

A Combination Strategy Targeting Enhancer Plasticity Exerts Synergistic Lethality Against Beti-Resistant Leukemia Cells

Lei Guo, PhD, Jia Li, PhD, Hongxiang Zeng, PhD, Anna Guzman, Tingting Li, MD, Minjung Lee, MS, Yubin Zhou, PhD, Clifford Stephan, Peter J.A Davies, Margaret Goodell, PhD, Deqiang Sun, PhD, Mark A. Dawson, PhD MBBS, Yun Huang, PhD

Blood (2019) 134 (Supplement_1): 5053.

https://doi.org/10.1182/blood-2019-130586

Published: 2019

Journal Articles

Molecular Characterization of EP300 Mutant Myeloid Neoplasia

Sunisa Kongkiatkamon, Yasunobu Nagata, MD PhD, Hassan Awada, Vera Adema, PhD, Cassandra M Kerr, MS, Kevin Fung, Francesca Gould, Christina Snider, Milo Co, Jibran Durrani, Hetty E. Carraway, MD MBA, Mikkael A. Sekeres, MD MS, Valeria Visconte, PhD, Jaroslaw P. Maciejewski, MD PhD

Blood (2019) 134 (Supplement_1): 5043.

https://doi.org/10.1182/blood-2019-130986

Published: 2019

Journal Articles

Oncolytic Virus Therapy with HSV-1 for Hematologic Malignancies

Ryo Ishino, Yumi Kawase, MD, Toshio Kitawaki, MD PhD, Naoshi Sugimoto, MD PhD, Maki Oku, MD, Shumpei Uchida, MD, Osamu Imataki, MD PhD, Akihito Matsuoka, MD PhD, Teruhisa Taoka, MD PhD, Kimihiro Kawakami, MD PhD, Tomoki Todo, MD PhD, Akifumi Takaori-Kondo, MD PhD, Norimitsu Kadowaki, MD PhD

Blood (2019) 134 (Supplement_1): 3242.

https://doi.org/10.1182/blood-2019-127754

Published: 2019

Journal Articles

Polatuzumab Vedotin Plus Bendamustine with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Updated Results of a Phase Ib/II Randomized Study

Laurie H Sehn, MD, Matthew J Matasar, MD, Christopher R. Flowers, MD MS, Manali Kamdar, MD MD, Andrew K McMillan, FRCP, Mark Hertzberg, MD MBBS, PhD, Sarit Assouline, MD, Tae Min Kim, MD PhD, Won Seog Kim, MD PhD, Muhit Ozcan, MD, Brandon Croft, PharmD, Jamie Hirata, PharmD, Ji Cheng, PhD, Grace Ku, MD, Alex F. Herrera, MD

Blood (2019) 134 (Supplement_1): 4081.

https://doi.org/10.1182/blood-2019-123449

Published: 2019

Journal Articles

A 20-Year Review of Imatinib in Chronic Phase Chronic Myeloid Leukemia Patients after Failure with Interferon Therapy

Maria R Vazquez, Hagop M. Kantarjian, MD, Gautam M. Borthakur, MD, Susan O'Brien, MD, Srdan Verstovsek, MD PhD, Farhad Ravandi, MD, Alessandra Ferrajoli, MD, Jorge E. Cortes, MD, Tapan M. Kadia, MD, William G. Wierda, MD PhD, Guillermo Garcia-Manero, MD, Sara E Dellasala, BS, Kathleen A Kehr, MD, Sherry A. Pierce, BSN, BA, Mary B. Rios, RN, Elias Jabbour, MD

Blood (2019) 134 (Supplement_1): 2927.

https://doi.org/10.1182/blood-2019-132246

Published: 2019

Journal Articles

Second Primary Malignancy Among Patients with Plasma Cell Myeloma Receiving First-Line Lenalidomide-Based Therapy: A Population-Based Analysis

Smith Giri, MBBS, Peter Barth, MD, Luciano J. Costa, MD PhD, Adam J Olszewski, MD

Blood (2019) 134 (Supplement_1): 1862.

https://doi.org/10.1182/blood-2019-131231

Published: 2019

Journal Articles

Incidence of Second Primary Malignancies and Association with Treatment in US Veterans with Multiple Myeloma

Nathanael Fillmore, PhD, Sarvari Venkata Yellapragada, MD, Cenk Yildirim, MS, Aimaz Afrough, MD, Adanma Anji Ayanambakkam Attanathi, MD, Ifeorah Chizoba, MPH, Nhan Do, MD, Mary Brophy, MD MPH, Nikhil C. Munshi, MD

Blood (2019) 134 (Supplement_1): 1806.

https://doi.org/10.1182/blood-2019-132227

Published: 2019

Journal Articles

Chromosome 1q Amplification Is Associated with a History of Prior Malignancies Among Patients Newly Diagnosed with Multiple Myeloma

Elizabeth B Lamont, MD MS, MMSc, Andrew J. Yee, MD, Stuart L. Goldberg, MD, Andrew D Norden, MD MPH, MBA

Blood (2019) 134 (Supplement_1): 2193.

https://doi.org/10.1182/blood-2019-125407

Published: 2019

Journal Articles

Blocking Lysosomal Two-Pore Channel 2 Function Inhibits Proliferation of Multidrug Resistant Leukemia Cells and Sensitizes Them to Vincristine Treatment

Martin Müller, MSc, Franz Geisslinger, Susanne Gerndt, Ramona Schütz, Yu-Kai Chao, Franz Bracher, Christian Grimm, Angelika Vollmar, Karin Bartel

Blood (2019) 134 (Supplement_1): 2081.

https://doi.org/10.1182/blood-2019-128195

Published: 2019

Journal Articles

Incidence of VTE Among Patients with a Cancer Diagnosis in Oklahoma County

Micah Denay McCumber, BS, MS, Aaron Mark Wendelboe, PhD MS, Janis Campbell, PhD GISP, Kai Ding, PhD, Michele G Beckman, MPH, Nimia L Reyes, MD MPH, Gary E. Raskob, PhD

Blood (2019) 134 (Supplement_1): 3463.

https://doi.org/10.1182/blood-2019-130604

Published: 2019

Journal Articles

Second Cancers in Adults with Acute Promyelocytic Leukemia (APL) Treated with or without Arsenic Trioxide (ATO): A SEER-Medicare Analysis

Kelly J. Norsworthy, MD, Steven T. Bird, PhD PharmD, MS, Armen Avagyan, MS, Yuchen Li, MS, Sandia Akhtar, BS, Jiemin Liao, MA, Michael Wernecke, BA, Albert B. Deisseroth, MD PhD, Meredith Chuk, MD, Thomas E. MaCurdy, PhD, Richard Swain, PhD, Jeffrey A. Kelman, MD MMSc, Ann T. Farrell, MD, Richard Pazdur, MD, Gideon Blumenthal, MD, David J. Graham, MD MPH

Blood (2019) 134 (Supplement_1): 3497.

https://doi.org/10.1182/blood-2019-130295

Published: 2019

Journal Articles

Targeting the Glyco-Antigen CD75s with the Tetravalent, Fc-Engineered Antibody 'Ebu-141 Tetra' Induces Potent Killing of B Cell Lymphoma and Plasma Cell Tumors

Katja Klausz, PhD, Amir Karimzadeh-Tabrizi, Malena Buck, Steffen Krohn, Anna-Kathrin Otte, PhD, Christian Kellner, PhD, Giorgio Alberto Croci, MD, Wolfram Klapper, MD, Matthias Peipp, PhD, Martin Gramatzki, MD

Blood (2018) 132 (Supplement 1): 4178.

https://doi.org/10.1182/blood-2018-99-118068

Published: 2018

Journal Articles

PTHrP May Contribute to Cachexia Accompanying Multiple Myeloma Bone Disease

Attaya Suvannasankha, MD, Colin Crean, BS, Isaac Carrera Ochoa, G David Roodman, MD PhD, John Chirgwin, PhD

Blood (2018) 132 (Supplement 1): 4450.

https://doi.org/10.1182/blood-2018-99-115680

Published: 2018

Journal Articles

Monoclonal Gammopathy of Undetermined Significance - Patient Characteristics and Referral Patterns

Holly Lee, MD, Lesley Street, MD, Jason Tay, MD, Jennifer Grossman, MD, John F Thaell, MD, Dawn Goodyear, MD, Sylvia McCulloch, MD, Peter Duggan, MD, Paola Neri, MD, Victor Jimenez-Zepeda, MD

Blood (2018) 132 (Supplement 1): 4496.

https://doi.org/10.1182/blood-2018-99-117930

Published: 2018

Journal Articles

The Histone Demethylase KDM4A Is Required to Sustain H3K9me3/H3K27me3 Epigenetic States and Oncogenesis in MLL-AF9 Acute Myeloid Leukemia

Matthew E Massett, BSc, Niamh Mannion, BSc,PhD, Laura Monaghan, BSc, Joana Bittencourt-Silvestre, BSc, MSc, Sandra Marmiroli, BSc,PhD, Robert M J Liskamp, BSc, PhD, Alison M Michie, BSc, PhD, David Vetrie, BSc, PhD, Xu Huang, BSc, PhD

Blood (2018) 132 (Supplement 1): 3879.

https://doi.org/10.1182/blood-2018-99-111256

Published: 2018

Journal Articles

Survivorship in AML - Outcomes of Acute Myelogenous Leukemia (AML) Patients (pts) after Maintaining Complete Remission (CR) for at Least 3 Years (yrs)

Catherine Kendall Major, BS, Hagop M. Kantarjian, MD, Gautam Borthakur, MD, Tapan M. Kadia, MD, Naveen Pemmaraju, MD, Nicholas J Short, MD, Naval G. Daver, MD, Elias J. Jabbour, MD, Richard E Champlin, MD, Guillermo Garcia-Manero, MD, Marina Y. Konopleva, MD PhD, Michael Andreeff, MD PhD, Steven M. Kornblau, MD, William G. Wierda, MD PhD, Sherry A. Pierce, BSN, BA, Farhad Ravandi, MD, Jorge E. Cortes, MD

Blood (2018) 132 (Supplement 1): 3976.

https://doi.org/10.1182/blood-2018-99-119892

Published: 2018

Journal Articles

Outcomes of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients (pts) Surviving More Than 5 Years (yrs) after Initial Therapy with TKIs

Blood (2018) 132 (Supplement 1): 5442.

https://doi.org/10.1182/blood-2018-99-119995

Published: 2018

NARROW

Comprehensive Analysis of Genotype and Prior Exposures in Therapy-Related Myeloid Neoplasms (t-MNs)

NCAPD3 Regulates Tumor Growth and Predicts Prognosis in Diffuse Large B-Cell Lymphoma

Development of an Immunotherapeutic Monoclonal Antibody Recognizing DKK1-HLA-A2 Complex to Treat Human Hematologic Malignancies

A Combination Strategy Targeting Enhancer Plasticity Exerts Synergistic Lethality Against Beti-Resistant Leukemia Cells

Molecular Characterization of EP300 Mutant Myeloid Neoplasia

Oncolytic Virus Therapy with HSV-1 for Hematologic Malignancies

Polatuzumab Vedotin Plus Bendamustine with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Updated Results of a Phase Ib/II Randomized Study

A 20-Year Review of Imatinib in Chronic Phase Chronic Myeloid Leukemia Patients after Failure with Interferon Therapy

Second Primary Malignancy Among Patients with Plasma Cell Myeloma Receiving First-Line Lenalidomide-Based Therapy: A Population-Based Analysis

Incidence of Second Primary Malignancies and Association with Treatment in US Veterans with Multiple Myeloma

Chromosome 1q Amplification Is Associated with a History of Prior Malignancies Among Patients Newly Diagnosed with Multiple Myeloma

Blocking Lysosomal Two-Pore Channel 2 Function Inhibits Proliferation of Multidrug Resistant Leukemia Cells and Sensitizes Them to Vincristine Treatment

Incidence of VTE Among Patients with a Cancer Diagnosis in Oklahoma County

Second Cancers in Adults with Acute Promyelocytic Leukemia (APL) Treated with or without Arsenic Trioxide (ATO): A SEER-Medicare Analysis

Targeting the Glyco-Antigen CD75s with the Tetravalent, Fc-Engineered Antibody 'Ebu-141 Tetra' Induces Potent Killing of B Cell Lymphoma and Plasma Cell Tumors

PTHrP May Contribute to Cachexia Accompanying Multiple Myeloma Bone Disease

Monoclonal Gammopathy of Undetermined Significance - Patient Characteristics and Referral Patterns

The Histone Demethylase KDM4A Is Required to Sustain H3K9me3/H3K27me3 Epigenetic States and Oncogenesis in MLL-AF9 Acute Myeloid Leukemia

Survivorship in AML - Outcomes of Acute Myelogenous Leukemia (AML) Patients (pts) after Maintaining Complete Remission (CR) for at Least 3 Years (yrs)

Outcomes of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients (pts) Surviving More Than 5 Years (yrs) after Initial Therapy with TKIs

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only